Core Viewpoint - The approval of ALMB-0166 for Phase II clinical trials in China represents a significant advancement in the treatment of Parkinson's disease, addressing a critical need for new therapies in this area [1][2]. Group 1: Company Developments - The company, Shiyao Group, has announced that its developed drug ALMB-0166 has received approval from the National Medical Products Administration of China to conduct Phase II clinical trials for evaluating its efficacy in patients with Parkinson's disease [1]. - ALMB-0166 is a first-in-class humanized monoclonal antibody inhibitor targeting the novel target Connexin 43 (Cx43), developed by the company's subsidiary, AlaMab Therapeutics Inc. [1]. - The company is committed to advancing the clinical research of ALMB-0166 across various indications, aiming for its swift market launch [3]. Group 2: Industry Context - Parkinson's disease is the second most common neurodegenerative disease globally, characterized by the progressive degeneration of dopamine neurons in the substantia nigra and the formation of Lewy bodies [2]. - Current treatments, primarily based on levodopa, only alleviate symptoms without reversing disease progression or achieving a cure, highlighting the urgent need for new therapeutic options [2]. - ALMB-0166 targets Cx43 hemichannels to inhibit the release and spread of neuroinflammatory factors, maximizing neuroprotection, and preclinical studies have shown significant efficacy in preserving dopamine levels and restoring behavioral functions in animal models [2].
石药集团(01093)：ALMB-0166在中国获临床试验批准用于治疗帕金森氏症